Compare Recursion Pharmaceuticals Inc (RXRX) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while ABRDN Physical Gold Shares ETF trades at $38.89. The key difference: ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SGOL | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $6.79 | $51.41 |
52-Week Low | $2.84 | $31.18 |
Enterprise Value | $946.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
SGOL is trading at $38.16, down 0.16% with bearish technical signals dominating. The stock shows 16 sell signals versus only 1 buy signal across technical indicators, with moving averages indicating strong bearish momentum. Recent gold market volatility and interest rate expectations are creating headwinds for gold-related assets. The stock lacks available fundamental data for traditional valuation metrics.
The outlook remains cautious given the bearish technical setup and gold market uncertainty. Investment opportunities exist for contrarian investors betting on gold's safe-haven appeal amid geopolitical tensions. Key risks include continued interest rate pressure, gold price volatility, and the stock's technical weakness potentially extending further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
